

MLS AND MLT PRACTICE ANALYSIS REPORT

For Development of
MLT(ASCP) & MLT(ASCPⁱ)
and
MLS(ASCP) & MLS(ASCPⁱ)
Content Guidelines and Examinations
for Exam Publication January 1, 2019

Copyright © 2018 by the ASCP Board of Certification. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, online or otherwise, without prior written permission in writing from ASCP Board of Certification.

TABLE OF CONTENTS

| | |
|---|----------------|
| Introduction..... | 3 |
| Practice Analysis Process..... | 3 |
| Survey Development..... | 4 |
| Demographics..... | 4 |
| Task Inventory – Knowledge and Skill Questions..... | 4 |
| Rating Criteria..... | 4 |
| Survey Construction..... | 5 |
| Pilot Testing and Revision..... | 5 |
| Survey Distribution..... | 5 |
| Survey Analysis..... | 5 |
| Committee Review and Discussion..... | 5 – 6 |
| Examination Content Guideline, Standard Setting, and Exam Publication..... | 6 |
| Appendices | |
| Appendix A – Medical Laboratory Technician (MLT) Demographic Analysis..... | 7 |
| Appendix B – Medical Laboratory Technician (MLT) Final Task List..... | 8 – 19 |
| Appendix C – Medical Laboratory Scientist (MLS) Demographic Analysis..... | 20 |
| Appendix D – Medical Laboratory Scientist (MLS) Final Task List..... | 21 – 34 |

INTRODUCTION

The purpose of conducting a practice analysis (a.k.a. job analysis or job task analysis) is to provide the foundation of a certification examination by defining practice in a profession. The practice analysis provides evidence of content validation. It is required by psychometric standards and is considered best practices for high-stakes examination development. It also ensures the certification examination is fair, valid, job-related, and most importantly, legally defensible (Chinn and Hertz 2010)¹. The ASCP Board of Certification (BOC) conducts a practice analysis approximately every five years in accordance with ASCP BOC Policy and requirements of the accrediting body, ANSI (American National Standards Institute), under ANSI/ISO/IEC 17024:2012.

A practice analysis is a formal process for determining or verifying the responsibilities of individuals in the job/profession, the knowledge individuals must possess, and the skills necessary to perform the job at a minimally competent level. The practice analysis process provides a complete and modern understanding of the duties and functions of practicing laboratory professionals. The results of the practice analysis inform the specifications and content of the ASCP BOC certification examinations. The practice analysis process ensures that the examinations are reflective of current practices. It also helps guarantee that individuals who become certified are current and up-to-date on the state of medical laboratory science practice and are competent to perform as certified laboratory professionals.

PRACTICE ANALYSIS PROCESS

ASCP BOC conducted a practice analysis survey to inform the following certification examination categories:

- Medical Laboratory Technician (MLT)
- Medical Laboratory Scientist (MLS)
- Technologist in Blood Banking (BB)
- Specialist in Blood Banking (SBB)
- Technologist in Chemistry (C)
- Specialist in Chemistry (SC)
- Technologist in Hematology (H)
- Specialist in Hematology (SH)
- Technologist in Microbiology (M)
- Specialist in Microbiology (SM)

The process for conducting a practice analysis consists of the following steps:

1. Survey Development
2. Demographics
3. Task Inventory – Knowledge and Skill Questions
4. Rating Criteria
5. Survey Construction
6. Pilot Testing and Revision
7. Survey Distribution
8. Survey Analysis
9. Committee Review and Discussion
10. Examination Content Guideline, Standard Setting, and Exam Publication

¹ Chinn, R.N., and N.R. Hertz. 2010. *Job Analysis: A Guide for Credentialing Organizations*. Lexington: Council on Licensure, Enforcement and Regulation (CLEAR).

SURVEY DEVELOPMENT

During the 2015 ASCP BOC examination committee meetings, the five categorical examination committees (Blood Banking [BB], Chemistry [C], Hematology [H], Microbiology [M] and Molecular Biology [MB]) provided the input and discussion to develop the practice analysis survey for ten certification categories including the generalist categories of MLT and MLS as well as the technologist categories (BB, C, H and M) and specialist categories (SBB, SC, SH and SM). Each committee created the sections of the survey corresponding to their respective disciplines. The Joint Generalist Committee (MLT & MLS), whose membership includes representatives (mainly educators) from each categorical examination committee, reviewed and approved a final version of the survey for MLT and MLS. The committee members (subject matter experts) collectively discussed all pertinent aspects of their profession to design a concise survey to extract useful feedback from field professionals while maximizing response rate. The survey had two main components: demographics and task inventory with appropriate rating scales for each.

DEMOGRAPHICS

The demographic questions asked about experience, education, gender, age, titles, work shift, type of facility, areas of lab work, work hours, etc. The purpose of these questions was to aid the committee in deciding whether the sample of respondents obtained was representative of the profession in general. The demographic data provided analytic categories that allowed refinement of the survey population to utilize only those responses from individuals at the targeted professional level.

TASK INVENTORY – KNOWLEDGE AND SKILL QUESTIONS

The survey was broken into two core areas: knowledge and skills. The categorical examination committees and the Joint Generalist Committee developed a series of knowledge areas and job-related task questions that formed the body of the survey.

This survey had eleven major sections:

- Laboratory Operations
- Blood Banking
- Microbiology
- Chemistry
- Hematology/Coagulation
- Molecular Biology
- Immunology/Serology
- Urinalysis
- Body Fluids
- Point-of-Care Testing
- Management/Supervision

Respondents only rated the tasks within the major sections in which they work. All respondents rated the tasks within the Laboratory Operations section. For example, if a respondent indicated they currently work in Chemistry and Hematology, they rated tasks within those two sections and Laboratory Operations and did not see any other sections of the survey.

RATING CRITERIA

Different rating scales were used to assess the knowledge and skills on the survey. One rating scale was used for the knowledge-only tasks and asked respondents to assess the significance of having that knowledge to perform their job. The rating scale used for the skill-related tasks assessed whether respondents performed the specific task or not in their jobs.

SURVEY CONSTRUCTION

The practice analysis survey was created and delivered through Key Survey, an electronic survey vendor from Highroad Solution. Using an electronic tool allowed survey review and testing via the internet, email tracking of respondents using email addresses, and the ability to send email reminders for completion of the survey.

PILOT TESTING AND REVISION

The Joint Generalist Committee tested a pilot version of the survey. They reviewed and revised different aspects of the survey (e.g., information correctness, grammar/spelling errors, electronic glitches, correct survey branching, etc.). The pilot testing comments and edits informed the final version of the survey.

SURVEY DISTRIBUTION

The categorical and Joint Generalist Committees determined that the survey should be sent to all current generalist certificants (MLT and MT/MLS), categorical certificants (BB, C, H and M) and specialist certificants (SBB, SC, SH and SM) in the ASCP BOC Personify database. The survey was open for a five-week period between November 9, 2015 – December 14, 2015. ASCP BOC staff also directly emailed the survey to the categorical committees and encouraged the committee membership to disseminate the survey to their colleagues. Additionally, the survey link was posted on ASCP social media sites (e.g., Facebook and Twitter).

In an effort to garner more responses from individuals working in blood centers, ASCP BOC staff also reached out to the Qualification in Apheresis Work Group and the AABB. These contacts distributed the DPT survey link to several blood centers and placed the link in an AABB newsletter.

SURVEY ANALYSIS

The tasks were divided amongst eleven major sections (Laboratory Operations, Blood Banking, Chemistry, Microbiology, Hematology/Coagulation, Molecular Biology, Immunology/Serology, Urinalysis, Body Fluids, Point-of-Care Testing, and Management/Supervision). All respondents saw the Laboratory Operations category. Because respondents only rated the tasks within the other major categories in which they practice, the number of respondents vary for each of the other sections depending on the number of respondents who indicated that they currently work in that area.

Responses from individuals performing higher-level supervisory tasks were not appropriate for an entry-level generalist or technologist certification categories were included for analysis with the specialist exam categories. Any individuals not currently practicing (e.g., retired, unemployed, or simply not working as a laboratory professional) were removed from the practice analysis survey.

COMMITTEE REVIEW AND DISCUSSION

During the 2016 examination committee meetings, the Blood Banking, Chemistry, Hematology, and Microbiology Committees reviewed the practice analysis results. They agreed that the demographic results accurately reflected the MLT and MLS population (**Appendices A & C**).

Each categorical exam committee reviewed the tasks within their area of expertise. In general tasks performed by at least 40% of the respondents would be retained on the task list and considered valid to be on the examination. These committees reviewed all tasks performed by less than 40% of the respondents. If the committee determined that these tasks were critical to patient care and/or were up-and-coming in practice, then the task was retained on the task list and considered valid for the examination. If the task was considered outdated or too esoteric, then it would be removed from the task

list and the exam. Because only a small percentage of the MLS population reported performing management/supervisory tasks, the Management/Supervisory section did not provide useful data. The Joint Generalist Committee then reviewed the decisions made by the aforementioned committees and produced the Final Task Lists for MLT and MLS (**Appendices B & D**) which informed the exam content guidelines and the content for the certification exams.

EXAMINATION CONTENT GUIDELINE, STANDARD SETTING, AND EXAM PUBLICATION

The committees revised the MLT and MLS exam content guidelines to reflect the practice analysis results. They reviewed the exam content area percentages and decided where to set them based on the results of the practice analysis. The committees reviewed the exam databases according to the new content guidelines and deleted or revised questions accordingly. They wrote new questions to fulfill the new content guidelines, and reclassified questions according to the new guidelines. After this work was completed, the committees set a new standard for each exam, and the new exam databases were published.

MEDICAL LABORATORY TECHNICIAN (MLT) DEMOGRAPHIC ANALYSIS

Total respondents: 4,348

Total usable: 753

Usable individual respondents met the following criteria:

- Currently employed as a medical laboratory professional in a clinical laboratory or blood center
- Currently working as a non-supervisory technician/MLT

Summary:

- Certifications: nearly all (98%) are MLT certified
- Education:
 - 6% have less than an associate degree
 - 75% have an associate degree
 - 19% have a baccalaureate degree or higher
- Experience:
 - 58% have less than 10 years
 - 15% have 10 – 20 years
 - 27% have 20 or more years
- Geographic Distribution: there are respondents from all fifty U.S. states, Washington D.C. and Puerto Rico, and states with the highest response rate include:
 - 8% each from Minnesota and Texas
 - 7% from Ohio
 - 5% each from Illinois, Pennsylvania, and Wisconsin
 - 4% from Indiana, Michigan, and Missouri
- Facility:
 - 73% work in hospitals
 - 14% work in physician offices/clinics
 - 6% work in independent labs
 - 7% are employed in various types of facilities
- Age:
 - 22% are younger than 30 years of age
 - 71% are 30 – 59 years of age
 - 7% are over 60 years of age
- Gender:
 - 85% are female
 - 14% are male
 - 1% chose not to answer this question

MEDICAL LABORATORY TECHNICIAN (MLT)

FINAL TASK LIST (TOPICS KEPT ON EXAM BASED ON PRACTICE ANALYSIS RESULTS)

| LABORATORY OPERATIONS |
|---|
| SPECIMEN COLLECTION, PREPARATION, AND PROCESSING |
| 1. Proper collection/procurement and labeling of specimens |
| 2. Guidance/assistance to healthcare providers regarding test orders and procedures |
| 3. Chain of custody procedures |
| 4. Specimen processing (e.g., centrifuge, separate) |
| 5. Specimen storage (e.g., time, temperature, light) |
| 6. Specimen distribution (e.g., packaging to meet USPS, DOT and/or IATA regulations/requirements) |
| 7. Specimen evaluation for acceptability |
| 8. Corrective action for unsatisfactory specimens |
| REPORTING AND INTERPRETING RESULTS |
| 9. Autoverification of patient results |
| 10. Result reporting during LIS/computer downtime |
| 11. Manual result entry (e.g., add interpretive comments, reference, or resource information to the report) |
| 12. Correlation of test results with other data (e.g., clinical history, other lab results) and take corrective action as necessary |
| 13. Critical result reporting according to protocol |
| 14. Communication with healthcare providers regarding test results (e.g., report interpretation, amended results) |
| INSTRUMENTATION |
| 15. Balances |
| 16. Centrifuges (e.g., microhematocrit, cytocentrifuge) |
| 17. Microscopes |
| 18. Digital imagers (e.g., IRIS, CellaVision) |
| LABORATORY OPERATIONS |
| 19. Reagent preparation, labeling, and storage |
| 20. Reagent log maintenance |
| 21. Temperature log maintenance |
| 22. Calculations and unit conversions (e.g., dilutions, reagent preparation, graphs, statistics) |
| 23. Instrument troubleshooting and repair |
| 24. Instrument maintenance and calibration |
| 25. Equipment (e.g., pipettes) maintenance and calibration |
| 26. Evaluation/verification/validation of new instrumentation, methodologies, or assays |

- | |
|--|
| 27. Safety activities (e.g., PPE, fume hoods, fire, safety data sheets, biosafety cabinet) |
| 28. Hazard disposal, decontamination, and storage |
| 29. Regulatory compliance (e.g., HIPAA, OSHA, EPA, homeland security, state, and local) |
| 30. Quality control performance and review (e.g., IQCP) |
| 31. Routine corrective action follow-up of 'Out of Control' results |
| 32. Proficiency testing participation |
| 33. Competency Testing Program participation |
| 34. Quality Assurance Program participation |
| 35. Training of new staff |
| 36. Training of students, residents, and/or fellows |
| 37. Appropriate notification of reportable diseases |
| 38. Maintenance of patient records and laboratory database |
| 39. Departmental policy/procedure writing, review, and revision |

MOLECULAR DIAGNOSTICS

KNOWLEDGE QUESTIONS

- | |
|--|
| 40. Nucleic acid chemistry and basic molecular theory (e.g., DNA structure, mutation, transcription) |
| 41. Biochemical reagents (e.g., DNA ligase, polymerase enzymes) |
| 42. Genetics (e.g., human, microbial) |
| 43. Correlation of patient results with disease states |

MOLECULAR TECHNIQUES

- | |
|--|
| 44. Specimen collection and/or handling protocols for molecular testing |
| 45. Processing of specimens for molecular testing (e.g., extract RNA/DNA, evaluate quality/quantity of nucleic acid, store nucleic acid) |
| 46. Nucleic acid amplification (e.g., PCR, PCR variations, SDA, TMA, NASBA, bDNA) |
| 47. Separation techniques (e.g., electrophoresis) |
| 48. Hybridization methods (e.g., Southern Blot, array technology, FISH, colony blot) |
| 49. Prevention, detection, and removal of nucleic acid contamination |

MOLECULAR TESTING

Infectious Disease

- | |
|---|
| 50. Chlamydia/N. gonorrhoeae |
| 51. MRSA/MSSA |
| 52. Respiratory pathogens (e.g., influenza, legionella, bordetella, adenovirus) |
| 53. C. difficile |
| 54. Gastrointestinal pathogens |
| 55. Group B Strep |

Hematology/Oncology

- | |
|--|
| 56. Leukemias/Lymphomas (e.g., CML, ALL, translocations) |
|--|

MICROBIOLOGY

GENERAL PROCESSING AND RAPID TESTING

Specimen Processing

57. Routine bacteriology specimen processing (e.g., streaking plates, inoculating culture media, preparing slides for Gram stains)
58. Automated specimen processing (e.g., WASP, Kiestra, Previ)
59. Loading/unloading blood culture bottles on/from instrument
60. Direct specimen slide preparation for mycology (e.g., Calcofluor white, KOH)
61. Mycobacteriology specimen processing (e.g., digestion, decontamination, concentration, smear prep, media inoculation)
62. Parasitology specimen processing

Identify pathogens directly from specimens

63. Gram staining
64. Gram stain interpretation
65. Positive blood culture processing (e.g., Gram staining, streaking plates)
66. Direct molecular testing of positive blood cultures
67. Preliminary positive blood culture Gram stain result reporting
68. Interpretation of wet preparation smear (e.g., Trichomonas, calcofluor white)
69. Rapid antigen methods for bacteria (e.g., rapid Strep)
70. Rapid antigen methods for fungi (e.g., Cryptococcal antigen)
71. Rapid antigen methods for parasites (e.g., E. histolytica, Giardia, Malaria)
72. Rapid antigen methods for viruses (e.g., RSV, influenza)
73. Rapid molecular methods (e.g., BioFire, Nanosphere, Cepheid, Affirm VPIII)

ROUTINE BACTERIOLOGY (Including aerobes and anaerobes)

Identification/detection

74. Identification of aerobes by automated methods (e.g., Microscan, Vitek, Phoenix)
75. Identification of aerobes by commercial nonautomated methods (e.g., RapID, API)
76. Identification of aerobes by rapid/spot biochemical methods (e.g., oxidase, indole, catalase)
77. Identification of aerobes by conventional biochemical methods (e.g., urea, KIA, TSI, OF-sugars)
78. Serotyping methods (e.g., Strep grouping, Salmonella/Shigella typing)
79. Chromogenic agar methods (e.g., MRSA)
80. MALDI-TOF
81. Identification of anaerobes by full biochemical testing (e.g., Vitek, API, RapID)
82. Identification of anaerobes by identification disc and/or spot testing
83. Antigen and/or toxin detection direct from specimen (e.g., C. difficile, Shiga toxin)

Antimicrobial susceptibility testing

84. Automated microdilution (e.g., Microscan, Vitek, Phoenix)
85. Disk diffusion method (i.e., Kirby Bauer)
86. E-Test gradient method
87. Enzyme detection (e.g., beta-lactamase)
88. Resistance mechanism detection (e.g., D test, modified Hodge, ESBL, PBP2a)

89. Molecular detection of resistance genes

MYCOLOGY/ACTINOMYCETES

Identification of Yeasts

90. Automated methods (Microscan, Vitek)

91. Commercial nonautomated methods (e.g., RapID, API)

92. Conventional methods (e.g., cornmeal tween 80, germ tube)

93. Chromogenic agar methods

94. MALDI-TOF

Identification of Actinomycetes

95. MALDI-TOF

PARASITOLOGY

96. Pinworm preparation

97. Preparation of permanent stained smears (e.g., trichrome, iron hematoxylin)

98. Interpretation of permanent stained smears

99. Interpretation of direct exam from concentrate

100. Interpretation of blood films

SPIROCHETES, OBLIGATE INTRACELLULAR BACTERIA and MYCOPLASMAS

101. Molecular methods directly from specimen (e.g., *Chlamydia*, *N. gonorrhoeae* NAAT)

BODY FLUID TESTING

102. CSF analysis

103. Synovial fluid analysis (e.g., crystal analysis)

104. Serous body fluid (e.g., pericardial, peritoneal, pleural) analysis

105. Bronchoalveolar lavage (BAL) analysis

106. Gastric analysis (e.g., pH)

107. Semen analysis

108. Sweat test

109. Urine eosinophil testing

110. Occult blood testing

111. Fecal leukocyte testing

112. Automated cell counts

113. Manual cell counts

114. Cytospin prep

IMMUNOLOGY

KNOWLEDGE QUESTIONS

- 115. Immune response (i.e., cellular and humoral / primary and secondary)
- 116. Principles of antigen-antibody interaction (e.g., immunoglobulin class and antigen structure)
- 117. Complement (i.e., mechanisms, biologic properties)
- 118. Lymphocyte subsets (e.g., CD4+ T helper cells)
- 119. Diseases related to the immune system (e.g., hypersensitivities, immunodeficiencies, infections)

SEROLOGICAL TECHNIQUES

- 120. Specimen collection and/or handling protocols for serology
- 121. Agglutination techniques (e.g., latex, particle)
- 122. Enzyme immunoassay
- 123. Chemiluminescence immunoassay
- 124. Immunofluorescence

AUTOIMMUNITY

- 125. ANA/ENA/Anti-DNA
- 126. Thyroid antibodies (e.g., TSH receptor TG and/or TPO antibodies)
- 127. RF/anti-CCP
- 128. Celiac Antibodies
- 129. Parietal cell / intrinsic factor antibodies
- 130. Cryoglobulins

VIRAL/MICROBIAL TESTING

- 131. Nontreponemal syphilis testing (e.g., RPR)
- 132. Treponemal syphilis testing (e.g., MHATP, particle agglutination)
- 133. Immunity screening (e.g., rubella, measles, varicella zoster)
- 134. Hepatitis
- 135. HIV (e.g., p24 antigen, HIV antibody, CD4 counts)
- 136. CMV/EBV

BLOOD BANKING

KNOWLEDGE QUESTIONS

Blood Group Systems

- 137. Molecular basis of blood group system (e.g., red cell genotyping, platelet genotyping)
- 138. Antigens and antibodies (e.g., red cell, HLA, platelet, granulocyte)
- 139. Recognition of the role of blood groups in transfusion (e.g., immunogenicity, antigen frequency)

| |
|---|
| Physiology and Pathophysiology |
| 140. Physiology of blood (e.g., circulation and blood volume, composition and function of blood, abnormal physiology, cell survival, cell metabolism) |
| 141. Hemostasis and coagulation (e.g., coagulation factors and disorders, platelet functions and disorders) |
| 142. Hemolytic disease of the fetus and newborn (e.g., pathophysiology, detection, treatment, prevention) |
| 143. Anemias (e.g., pathophysiology, detection, treatment) |
| 144. Immune-hemolytic anemias: warm, cold, drug-induced (e.g., pathophysiology, detection, treatment) |
| 145. Adverse effects of transfusion |
| 146. Transplantation (e.g., testing and transfusion support of solid organ and stem cell recipients) |
| Blood Products |
| 147. Recognition of anticoagulants and preservatives |
| General Immunology |
| 148. Immune response (i.e., cellular and humoral / primary and secondary) |
| 149. Principles of antigen-antibody interaction (e.g., immunoglobulin class and antigen structure) |
| 150. Complement (e.g., mechanisms, biologic properties) |
| 151. Immunomodulatory medications (e.g., IVIg, monoclonal antibodies, steroids) |
| BLOOD PRODUCTS |
| Collecting Donor Blood |
| 152. Determination of donor acceptability (e.g., health history questions and physical findings, hemoglobin screen, allogeneic and autologous donors) |
| 153. Collection of donor blood/components by phlebotomy |
| 154. Collection of donor blood/components by apheresis |
| 155. Recognition and management of adverse donor reactions |
| Processing Donor Blood |
| 156. Adherence to FDA/AABB requirements for testing donor blood (e.g., viral markers, NAT, ABO/Rh, antibody screen/ID) |
| 157. Lookback and recall of donor products (e.g., positive test results, post-donation information) |
| 158. Labeling of donor blood and blood products |
| Component Preparation |
| 159. Preparation of blood components from whole blood (e.g., red cell, plasma, platelets, cryoprecipitate) |
| 160. Special processing of blood components (e.g., washing, irradiating, freezing/deglycerolizing) |
| Quality Control of Blood Products |
| 161. Maintenance of records from donor to final disposition |
| 162. Blood product quality control |
| Storage and Transportation of Blood Products |
| 163. Blood/component storage |
| 164. Blood/component transportation |
| TRANSFUSION PRACTICE |
| 165. Preparation of components for transfusion (e.g., storage, aliquoting, washing, thawing) |
| 166. Monitoring component therapy (e.g., transfusion guidelines) |
| 167. Selection and preparation of components for pediatric/neonatal/perinatal transfusion |

| |
|--|
| 168. Emergency/massive transfusion protocol |
| 169. Platelet support for refractory patients |
| 170. Therapeutic apheresis |
| 171. Investigation of adverse effects of transfusion |
| 172. Blood administration auditing |
| 173. Blood product inventory management |
| 174. Blood component issue and return |
| 175. Plasma derivatives and factor concentrates issue (e.g., IVIG, factor VIII) |
| |
| SEROLOGIC AND MOLECULAR TESTING |
| 176. Manual serologic testing for ABO, Rh, and antibody detection (i.e., screening) |
| 177. Automated serologic testing for ABO, Rh, and antibody detection (i.e., screening) |
| 178. Antibody identification |
| 179. Crossmatch/compatibility testing |
| 180. Direct antiglobulin testing (DAT) |
| 181. Phenotyping (e.g., K, S) |
| 182. Antibody titration |
| 183. Elutions |
| 184. Adsorptions |
| 185. Special techniques (e.g., enzyme testing, DTT) |
| 186. Transfusion reaction work-up |
| 187. Cell separations |
| 188. Molecular RBC genotyping |
| 189. Leukocyte and platelet testing |
| Hemolytic Disease of the Fetus and Newborn (HDFN) Work-up |
| 190. Determination of candidacy for RhIG administration |
| 191. Rosette test |
| 192. Kleihauer-Betke test |
| |
| |
| CHEMISTRY |
| KNOWLEDGE QUESTIONS |
| 193. Normal and abnormal physiology including metabolic pathways and disease states |
| 194. The physical and chemical properties of analytes |
| |
| ANALYTICAL TECHNIQUES |
| 195. Spectrophotometry and photometry (e.g., photometry - UV or infrared, fluorescence, nephelometry/turbidimetry, reflectance, chemiluminescence) |
| 196. Osmometry |
| 197. Electrophoresis (e.g., traditional, capillary, isoelectric focusing) |
| 198. Immunofixation |

| |
|--|
| 199. Electrochemistry (e.g., potentiometry, pH, pCO ₂ , pO ₂ , ion-selective electrodes) |
| CARBOHYDRATES |
| 200. Galactose and other reducing substances |
| 201. Glucose including fasting, post-prandial, tolerance testing, insulin tolerance and gestational challenge |
| 202. Tolerance testing to assess other carbohydrates (e.g., xylose, lactose) |
| 203. Lactate |
| 204. Ketones (e.g., beta-hydroxybutyrate) |
| 205. Glycated hemoglobin/Hemoglobin A1c |
| 206. Insulin and/or C-peptide |
| 207. Fructosamine |
| LIPIDS |
| 208. Cholesterol including total, HDL, LDL (calculated and/or direct) |
| 209. Triglycerides |
| 210. Apolipoproteins (A & B) |
| 211. Chylomicron |
| HEME DERIVATIVES |
| 212. Hemoglobins (e.g., electrophoresis) |
| 213. Myoglobin |
| 214. Bilirubin |
| 215. Iron/TIBC |
| 216. Ferritin |
| PROTEINS AND OTHER NITROGEN-CONTAINING COMPOUNDS |
| 217. Total Protein (including albumin) |
| 218. Urine albumin (high sensitivity, microalbumin) |
| 219. Protein electrophoresis |
| 220. Immunofixation electrophoresis |
| 221. Newborn screening (e.g., amino acids, inborn errors of metabolism) |
| 222. C3, C4 |
| 223. BNP |
| 224. Ceruloplasmin |
| 225. C-reactive protein/hsCRP |
| 226. Haptoglobin |
| 227. Immunoglobulins (IgG, IgA, IgM) |
| 228. IgE |
| 229. Transferrin |
| 230. Urea |
| 231. Uric acid |
| 232. Creatinine/eGFR |
| 233. Creatinine clearance |

| |
|--|
| 234. Ammonia |
| 235. Routine tumor markers, (e.g., CEA, PSA, CA125) |
| 236. Special tumor markers (e.g., AFP, thyroglobulin, CA15-3, CA19-9) |
| 237. Fetal fibronectin |
| 238. Troponin |
| 239. Nutritional markers (e.g., prealbumin) |
| ENZYMES |
| 240. Creatine kinase (CK-MB, CK-MM) |
| 241. Lactate dehydrogenase (LD) |
| 242. Alanine aminotransferase (ALT) |
| 243. Aspartate aminotransferase (AST) |
| 244. Alkaline phosphatase (ALP) |
| 245. Gamma-glutamyl transferase (GGT) |
| 246. Serum cholinesterase |
| 247. Lipase/Amylase |
| 248. Glucose 6-phosphate dehydrogenase (G-6-PD) |
| BLOOD GASES |
| 249. pO_2 , pCO_2 , pH |
| 250. Calculated blood gas parameters (e.g., $p50$, % saturation, base excess) |
| 251. Carbon monoxide |
| ELECTROLYTES |
| 252. Potassium, sodium, chloride, CO_2 , bicarbonate |
| 253. Sweat test |
| 254. Calcium |
| 255. Magnesium |
| 256. Phosphorus |
| 257. Osmolality (measured and calculated) |
| 258. Calculated electrolyte parameters (e.g., anion gap/osmolal gap) |
| HORMONES |
| 259. TSH |
| 260. Total T3 |
| 261. Free T3 |
| 262. Total and free T4 |
| 263. TSH stimulation |
| 264. Cortisol |
| 265. HCG (quantitative) |
| 266. Luteinizing hormone (LH)/Follicle stimulating hormone (FSH) |
| 267. Parathyroid hormone (PTH) |
| 268. Estrogens |

| |
|--|
| 269. Progesterone |
| 270. Testosterone |
| 271. Prolactin |
| 272. ACTH stimulation/dexamethasone suppression |
| 273. Renin/aldosterone |
| 274. 17-OH progesterone |
| 275. Growth hormone/IGF-1 |
| 276. ADH (AVP) |
| |
| VITAMINS |
| 277. Vitamin D |
| 278. Vitamin B12/Folate |
| 279. Homocysteine |
| 280. Miscellaneous vitamins (e.g., A, B6, C) |
| |
| TOXICOLOGY |
| 281. Ethanol |
| 282. Volatiles (e.g., ethylene glycol, methanol, isopropanol) |
| 283. Lead |
| 284. Heavy metals (e.g., arsenic, mercury, bismuth) |
| 285. Analgesics (e.g., acetaminophen, salicylates) |
| 286. Drugs of abuse – class analyses/screening |
| 287. Drugs of abuse – identification/confirmation/quantitation |
| 288. Trace elements (e.g., copper, selenium) |
| |
| THERAPEUTIC DRUG MONITORING |
| 289. Aminoglycosides (e.g., gentamicin) |
| 290. Cardioactive (e.g., digoxin) |
| 291. Anti-convulsants (e.g., phenobarbital, diazepam, topiramate, levetiracetam) |
| 292. Anti-depressants |
| 293. Immunosuppressants (e.g., tacrolimus, sirolimus) |
| |
| HEMATOLOGY |
| KNOWLEDGE QUESTIONS |
| 294. Normal and abnormal physiology of erythrocytes, leukocytes, and platelets (e.g., production, destruction, function) |
| 295. Physiology of hemostasis and thrombosis (e.g., pathways – extrinsic, intrinsic, common & fibrinolytic, vascular system) |
| 296. Correlation of patient results with disease states of erythrocytes, leukocytes, and hemostasis |
| |

| PERIPHERAL BLOOD EVALUATION |
|---|
| 297. Automated cell counts and differentials |
| 298. Peripheral blood smears for differentials (preparation and staining) |
| 299. Manual differentials and peripheral smear evaluation (e.g., WBC, RBC, and platelet) |
| 300. Manual cell counts (WBCs and platelets) |
| 301. Estimation of leukocyte and platelet counts from a stained blood smear |
| 302. Recognition of immature, reactive, malignant, or abnormal nucleated cells and leukocyte inclusions |
| 303. Recognition of abnormalities that will interfere with automated results (e.g., platelet clumps, lipemia) |
| 304. Correction of counts for the presence of nucleated red cells |
| 305. Description and grading of red cells according to size, color, shape and inclusions |
| HEMATOLOGY TESTING |
| 306. ESR (erythrocyte sedimentation rate) |
| 307. Manual hematocrit |
| 308. Fetal hemoglobin (Kleihauer Betke) |
| 309. Hemoglobin F (quantitative) |
| 310. Heinz body screen |
| 311. Automated reticulocyte count |
| 312. Reticulocyte count using microscopy |
| 313. Sick cell screen |
| 314. Calculate/evaluate RBC indices including MCV, MCH, MCHC, RDW |
| 315. Hemoglobin electrophoresis |
| 316. RBC enzymes (e.g., G-6-PD, pyruvate kinase) |
| 317. Blood parasite screens (e.g., malaria, Babesia) |
| 318. Flow cytometric phenotyping |
| 319. Molecular genetic testing (e.g., FISH, PCR) |
| HEMOSTASIS (COAGULATION) TESTING |
| 320. Semi-automated coagulation analyzer |
| 321. Automated coagulation analyzer |
| 322. PT/INR |
| 323. APTT |
| 324. Thrombin time |
| 325. Fibrinogen |
| 326. D-dimer |
| 327. Mixing studies |
| 328. Factor assays |
| 329. vWF assays |
| 330. Heparin neutralization/adsorption (e.g., Hepzyme) |
| 331. Heparin assay (anti-Xa assay) |
| 332. Hypercoagulability tests (e.g., protein C, protein S, antithrombin) |
| 333. Hypercoagulable molecular testing (e.g., Factor V Leiden, prothrombin gene mutation) |
| 334. Platelet function screening tests (e.g., PFA-100TM) |

URINALYSIS

KNOWLEDGE QUESTIONS

335. Normal and abnormal physiology of the urinary system

336. Correlation of patient results with disease states

URINALYSIS TASKS

337. Appearance (e.g., color, clarity)

338. Chemical exam (reagent strip)

339. Microscopic exam (e.g., casts, cells, crystals, artifacts)

340. Specific gravity by refractometer

341. Confirmatory testing for reducing substances (e.g., Clinitest)

342. Confirmatory testing for bilirubin (e.g., Ictotest)

343. Confirmatory testing for proteins (e.g., SSA)

344. Confirmatory testing for ketones (e.g., Acetest)

345. Osmolality

346. Qualitative pregnancy test

347. Automated urine reagent strip reading device

348. Automated urine sediment analyzer

MEDICAL LABORATORY SCIENTIST (MLS) DEMOGRAPHIC ANALYSIS

Total respondents: 4,348

Total usable: 2,004

Usable individual respondents met the following criteria:

- Currently employed as a medical laboratory professional in a clinical laboratory or blood center
- Currently working as a non-supervisory technologist/MT/MLS

Summary:

- Certifications: nearly 90% are MLS certified
- Education:
 - 3% have an associate degree or lower
 - 69% have a baccalaureate degree
 - 18% have a post-baccalaureate program certificate
 - 10% have a master's degree or higher
- Experience:
 - 45% have less than 10 years
 - 16% have 10 – 20 years
 - 39% have 20 or more years
- Geographic Distribution: there are respondents from all fifty U.S. states, Washington D.C. and Puerto Rico, and states with the highest response rate include:
 - 6% each from Texas and California
 - 5% each from Michigan and Wisconsin
 - 4% each from New York, Illinois, Florida, Ohio, Minnesota, and Pennsylvania
- Facility:
 - 81% work in hospitals
 - 8% work in independent labs
 - 4% work in physician offices/clinics
 - 7% are employed in various types of facilities
- Age:
 - 25% are younger than 30 years of age
 - 60% are 30 – 59 years of age
 - 15% are over 60 years of age
- Gender:
 - 83% are female
 - 16% are male
 - 1% chose not to answer this question

MEDICAL LABORATORY SCIENTIST (MLS)

FINAL TASK LIST (TOPICS KEPT ON EXAM BASED ON PRACTICE ANALYSIS RESULTS)

| LABORATORY OPERATIONS |
|---|
| SPECIMEN COLLECTION, PREPARATION, AND PROCESSING |
| 1. Proper collection/procurement and labeling of specimens |
| 2. Guidance/assistance to healthcare providers regarding test orders and procedures |
| 3. Chain of custody procedures |
| 4. Specimen processing (e.g., centrifuge, separate) |
| 5. Specimen storage (e.g., time, temperature, light) |
| 6. Specimen distribution (e.g., packaging to meet USPS, DOT and/or IATA regulations/requirements) |
| 7. Specimen evaluation for acceptability |
| 8. Corrective action for unsatisfactory specimens |
| REPORTING AND INTERPRETING RESULTS |
| 9. Autoverification of patient results |
| 10. Result reporting during LIS/computer downtime |
| 11. Manual result entry (e.g., add interpretive comments, reference, or resource information to the report) |
| 12. Correlation of test results with other data (e.g., clinical history, other lab results) and take corrective action as necessary |
| 13. Critical result reporting according to protocol |
| 14. Communication with healthcare providers regarding test results (e.g., report interpretation, amended results) |
| INSTRUMENTATION |
| 15. Balances |
| 16. Centrifuges (e.g., microhematocrit, cytocentrifuge) |
| 17. Microscopes |
| 18. Ocular micrometers |
| 19. Digital imagers (e.g., IRIS, CellaVision) |
| LABORATORY OPERATIONS |
| 20. Reagent preparation, labeling, and storage |
| 21. Reagent log maintenance |
| 22. Temperature log maintenance |
| 23. Calculations and unit conversions (e.g., dilutions, reagent preparation, graphs, statistics) |
| 24. Instrument troubleshooting and repair |
| 25. Instrument maintenance and calibration |
| 26. Equipment (e.g., pipettes) maintenance and calibration |

- | |
|--|
| 27. Evaluation/verification/validation of new instrumentation, methodologies, or assays |
| 28. Safety activities (e.g., PPE, fume hoods, fire, safety data sheets, biosafety cabinet) |
| 29. Hazard disposal, decontamination, and storage |
| 30. Regulatory compliance (e.g., HIPAA, OSHA, EPA, homeland security, state, and local) |
| 31. Quality control performance and review (e.g., IQCP) |
| 32. Routine corrective action follow-up of 'Out of Control' results |
| 33. Proficiency testing participation |
| 34. Competency Testing Program participation |
| 35. Quality Assurance Program participation |
| 36. Training of new staff |
| 37. Training of students, residents, and/or fellows |
| 38. Training of point-of-care operators |
| 39. Appropriate notification of reportable diseases |
| 40. Maintenance of patient records and laboratory database |
| 41. Departmental policy/procedure writing, review, and revision |

MOLECULAR DIAGNOSTICS

KNOWLEDGE QUESTIONS

- | |
|--|
| 42. Nucleic acid chemistry and basic molecular theory (e.g., DNA structure, mutation, transcription) |
| 43. Biochemical reagents (e.g., DNA ligase, polymerase enzymes) |
| 44. Genetics (e.g., human, microbial) |
| 45. Correlation of patient results with disease states |

MOLECULAR TECHNIQUES

- | |
|--|
| 46. Specimen collection and/or handling protocols for molecular testing |
| 47. Processing of specimens for molecular testing (e.g., extract RNA/DNA, evaluate quality/quantity of nucleic acid, store nucleic acid) |
| 48. Nucleic acid amplification (e.g., PCR, PCR variations, SDA, TMA, NASBA, bDNA) |
| 49. Separation techniques (e.g., electrophoresis) |
| 50. Hybridization methods (e.g., Southern Blot, array technology, FISH, colony blot) |
| 51. Nucleic acid sequencing (e.g., Sanger sequencing, pyrosequencing, next-generation sequencing) |
| 52. Prevention, detection, and removal of nucleic acid contamination |
| 53. Bacterial identification by sequencing (e.g., 16S ribosomal RNA) |

MOLECULAR TESTING

Infectious Disease

- | |
|---|
| 54. Hepatitis (e.g., HCV, HBV) |
| 55. HIV |
| 56. Surveillance of immunocompromised patients (e.g., EBV, CMV, BK) |
| 57. HSV |

| |
|--|
| 58. Chlamydia/N. gonorrhoeae |
| 59. MRSA/MSSA |
| 60. HPV |
| 61. Respiratory pathogens (e.g., influenza, legionella, bordetella, adenovirus) |
| 62. C. difficile |
| 63. Gastrointestinal pathogens |
| 64. Group B Strep |
| 65. Mycobacteria |
| Hematology/Oncology |
| 66. Leukemias/Lymphomas (e.g., CML, ALL, translocations) |
| Genetics |
| 67. Coagulopathies (e.g., Factor V Leiden, prothrombin, MTHFR) |
| |
| MICROBIOLOGY |
| GENERAL PROCESSING AND RAPID TESTING |
| Specimen Processing |
| 68. Routine bacteriology specimen processing (e.g., streaking plates, inoculating culture media, preparing slides for Gram stains) |
| 69. Automated specimen processing (e.g., WASP, Kiestra, Previ) |
| 70. Loading/unloading blood culture bottles on/from instrument |
| 71. Direct specimen slide preparation for mycology (e.g., Calcofluor white, KOH) |
| 72. Mycobacteriology specimen processing (e.g., digestion, decontamination, concentration, smear prep, media inoculation) |
| 73. Parasitology specimen processing |
| Identify pathogens directly from specimens |
| 74. Gram staining |
| 75. Gram stain interpretation |
| 76. Positive blood culture processing (e.g., Gram staining, streaking plates) |
| 77. Direct molecular testing of positive blood cultures |
| 78. Preliminary positive blood culture Gram stain result reporting |
| 79. Interpretation of wet preparation smear (e.g., Trichomonas, calcofluor white) |
| 80. Rapid antigen methods for bacteria (e.g., rapid Strep) |
| 81. Rapid antigen methods for fungi (e.g., Cryptococcal antigen) |
| 82. Rapid antigen methods for parasites (e.g., E. histolytica, Giardia, Malaria) |
| 83. Rapid antigen methods for viruses (e.g., RSV, influenza) |
| 84. Rapid molecular methods (e.g., BioFire, Nanosphere, Cepheid, Affirm VPIII) |
| |

ROUTINE BACTERIOLOGY (Including aerobes and anaerobes)

Identification/detection

- 85. Identification of aerobes by automated methods (e.g., Microscan, Vitek, Phoenix)
- 86. Identification of aerobes by commercial nonautomated methods (e.g., RapID, API)
- 87. Identification of aerobes by rapid/spot biochemical methods (e.g., oxidase, indole, catalase)
- 88. Identification of aerobes by conventional biochemical methods (e.g., urea, KIA, TSI, OF-sugars)
- 89. Serotyping methods (e.g., Strep grouping, Salmonella/Shigella typing)
- 90. Chromogenic agar methods (e.g., MRSA)
- 91. MALDI-TOF
- 92. Identification of anaerobes by full biochemical testing (e.g., Vitek, API, RapID)
- 93. Identification of anaerobes by identification disc and/or spot testing
- 94. Antigen and/or toxin detection direct from specimen (e.g., C. difficile, Shiga toxin)

Antimicrobial susceptibility testing

- 95. Manual microdilution
- 96. Automated microdilution (e.g., Microscan, Vitek, Phoenix)
- 97. Disk diffusion method (i.e., Kirby Bauer)
- 98. E-Test gradient method
- 99. Enzyme detection (e.g., beta-lactamase)
- 100. Resistance mechanism detection (e.g., D test, modified Hodge, ESBL, PBP2a)
- 101. Molecular detection of resistance genes
- 102. Anaerobic antimicrobial susceptibility testing

MYCOLOGY/ACTINOMYCETES

Identification of Yeasts

- 103. Automated methods (Microscan, Vitek)
- 104. Commercial nonautomated methods (e.g., RapID, API)
- 105. Conventional methods (e.g., cornmeal tween 80, germ tube)
- 106. Chromogenic agar methods
- 107. MALDI-TOF

Identification of Molds

- 108. Stain method (e.g., lactophenol cotton blue)
- 109. Conventional methods (e.g., Trichophyton agars, urease)
- 110. MALDI-TOF

Identification of Actinomycetes

- 111. Genus determination by modified acid fast stain and lysozyme
- 112. MALDI-TOF

PARASITOLOGY

- 113. Pinworm preparation
- 114. Macroscopic parasite identification (e.g., larvae, ticks, worms)
- 115. Preparation of permanent stained smears (e.g., trichrome, iron hematoxylin)
- 116. Interpretation of permanent stained smears
- 117. Interpretation of direct exam from concentrate

118. Interpretation of blood films

119. Preparation and interpretation of stained smear for coccidians (e.g., *Isospora*, *Cryptosporidium*, *Cyclospora*)

120. Preparation and interpretation of stained smear for microsporidia

MYCOBACTERIOLOGY

Identification

121. Molecular methods directly from specimen (e.g., GeneXpert)

122. DNA probe

123. Sequencing and/or HPLC

124. MALDI-TOF

SPIROCHETES, OBLIGATE INTRACELLULAR BACTERIA and MYCOPLASMAS

125. Molecular methods directly from specimen (e.g., *Chlamydia*, *N. gonorrhoeae* NAAT)

BODY FLUID TESTING

126. CSF analysis

127. Synovial fluid analysis (e.g., crystal analysis)

128. Serous body fluid (e.g., pericardial, peritoneal, pleural) analysis

129. Bronchoalveolar lavage (BAL) analysis

130. Gastric analysis (e.g., pH)

131. Semen analysis

132. Amniotic fluid cell count

133. Sweat test

134. Urine eosinophil testing

135. Occult blood testing

136. Fecal leukocyte testing

137. Automated cell counts

138. Manual cell counts

139. Cytospin prep

IMMUNOLOGY

KNOWLEDGE QUESTIONS

140. Immune response (i.e., cellular and humoral / primary and secondary)

141. Principles of antigen-antibody interaction (e.g., immunoglobulin class and antigen structure)

142. Complement (i.e., mechanisms, biologic properties)

143. Immunomodulatory medications (e.g., IVIg, monoclonal antibodies, steroids)

144. Lymphocyte subsets (e.g., CD4+ T helper cells)

145. Diseases related to the immune system (e.g., hypersensitivities, immunodeficiencies, infections)

SEROLOGIC TECHNIQUES

146. Specimen collection and/or handling protocols for serology

147. Agglutination techniques (e.g., latex, particle)

148. Enzyme immunoassay

149. Chemiluminescence immunoassay

150. Immunofluorescence

AUTOIMMUNITY

151. ANA/ENA/Anti-DNA

152. Thyroid antibodies (e.g., TSH receptor TG and/or TPO antibodies)

153. RF/anti-CCP

154. Celiac Antibodies

155. Parietal cell / intrinsic factor antibodies

156. Cryoglobulins

VIRAL/MICROBIAL TESTING

157. Nontreponemal syphilis testing (e.g., RPR)

158. Treponemal syphilis testing (e.g., MHATP, particle agglutination)

159. Immunity screening (e.g., rubella, measles, varicella zoster)

160. Hepatitis

161. HIV (e.g., p24 antigen, HIV antibody, CD4 counts)

162. CMV/EBV

163. Cytokine testing for tuberculosis (e.g., QuantiFERON)

164. Lyme disease testing

BLOOD BANKING

KNOWLEDGE QUESTIONS

Blood Group Systems

165. Molecular basis of blood group system (e.g., red cell genotyping, platelet genotyping)

166. Antigens and antibodies (e.g., red cell, HLA, platelet, granulocyte)

167. Recognition of the role of blood groups in transfusion (e.g., immunogenicity, antigen frequency)

Physiology and Pathophysiology

168. Physiology of blood (e.g., circulation and blood volume, composition and function of blood, abnormal physiology, cell survival, cell metabolism)

169. Hemostasis and coagulation (e.g., coagulation factors and disorders, platelet functions and disorders)

170. Hemolytic disease of the fetus and newborn (e.g., pathophysiology, detection, treatment, prevention)

171. Anemias (e.g., pathophysiology, detection, treatment)

172. Immune-hemolytic anemias: warm, cold, drug-induced (e.g., pathophysiology, detection, treatment)

173. Adverse effects of transfusion

| |
|---|
| 174. Transplantation (e.g., testing and transfusion support of solid organ and stem cell recipients) |
| Blood Products |
| 175. Recognition of anticoagulants and preservatives |
| General Immunology |
| 176. Immune response (i.e., cellular and humoral / primary and secondary) |
| 177. Principles of antigen-antibody interaction (e.g., immunoglobulin class and antigen structure) |
| 178. Complement (e.g., mechanisms, biologic properties) |
| 179. Immunomodulatory medications (e.g., IVIg, monoclonal antibodies, steroids) |
| BLOOD PRODUCTS |
| Collecting Donor Blood |
| 180. Determination of donor acceptability (e.g., health history questions and physical findings, hemoglobin screen, allogeneic and autologous donors) |
| 181. Collection of donor blood/components by phlebotomy |
| 182. Collection of donor blood/components by apheresis |
| 183. Recognition and management of adverse donor reactions |
| Processing Donor Blood |
| 184. Adherence to FDA/AABB requirements for testing donor blood (e.g., viral markers, NAT, ABO/Rh, antibody screen/ID) |
| 185. Lookback and recall of donor products (e.g., positive test results, post-donation information) |
| 186. Labeling of donor blood and blood products |
| Component Preparation |
| 187. Preparation of blood components from whole blood (e.g., red cell, plasma, platelets, cryoprecipitate) |
| 188. Special processing of blood components (e.g., washing, irradiating, freezing/deglycerolizing) |
| Quality Control of Blood Products |
| 189. Maintenance of records from donor to final disposition |
| 190. Blood product quality control |
| Storage and Transportation of Blood Products |
| 191. Blood/component storage |
| 192. Blood/component transportation |
| TRANSFUSION PRACTICE |
| 193. Preparation of components for transfusion (e.g., storage, aliquoting, washing, thawing) |
| 194. Monitoring component therapy (e.g., transfusion guidelines) |
| 195. Selection and preparation of components for pediatric/neonatal/perinatal transfusion |
| 196. Emergency/massive transfusion protocol |
| 197. Platelet support for refractory patients |
| 198. Therapeutic apheresis |
| 199. Investigation of adverse effects of transfusion |
| 200. Blood administration auditing |
| 201. Blood product inventory management |
| 202. Blood component issue and return |
| 203. Plasma derivatives and factor concentrates issue (e.g., IVIG, factor VIII) |

SEROLOGIC AND MOLECULAR TESTING

- 204. Manual serologic testing for ABO, Rh, and antibody detection (i.e., screening)
- 205. Automated serologic testing for ABO, Rh, and antibody detection (i.e., screening)
- 206. Antibody identification
- 207. Crossmatch/compatibility testing
- 208. Direct antiglobulin testing (DAT)
- 209. Phenotyping (e.g., K, S)
- 210. Antibody titration
- 211. Elutions
- 212. Adsorptions
- 213. Special techniques (e.g., enzyme testing, DTT)
- 214. Transfusion reaction work-up
- 215. Cell separations
- 216. Molecular RBC genotyping
- 217. Neutralization/inhibition
- 218. Leukocyte and platelet testing
- 219. Donath-Landsteiner testing
- 220. Thermal amplitude

Histocompatibility testing (e.g., HLA typing, HLA antibody screening)

- 221. Serologic
- 222. Molecular

Hemolytic Disease of the Fetus and Newborn (HDFN) Work-up

- 223. Determination of candidacy for RhIG administration
- 224. Rosette test
- 225. Flow cytometry
- 226. Kleihauer-Betke test

CHEMISTRY

KNOWLEDGE QUESTIONS

- 227. Normal and abnormal physiology including metabolic pathways and disease states
- 228. The physical and chemical properties of analytes

ANALYTICAL TECHNIQUES

- 229. Spectrophotometry and photometry (e.g., photometry - UV or infrared, fluorescence, nephelometry/turbidimetry, reflectance, chemiluminescence)
- 230. Mass spectrometry (e.g., GCMS, HPLC, tandem MS/MS, MALDI-TOF)
- 231. Osmometry
- 232. Electrophoresis (e.g., traditional, capillary, isoelectric focusing)
- 233. Immunofixation
- 234. Chromatography (e.g., thin layer, cation exchange)
- 235. Electrochemistry (e.g., potentiometry, pH, pCO₂, pO₂, ion-selective electrodes)

CARBOHYDRATES

- 236. Galactose and other reducing substances
- 237. Glucose including fasting, post-prandial, tolerance testing, insulin tolerance and gestational challenge
- 238. Tolerance testing to assess other carbohydrates (e.g., xylose, lactose)
- 239. Lactate
- 240. Ketones (e.g., beta-hydroxybutyrate)
- 241. Glycated hemoglobin/Hemoglobin A1c
- 242. Insulin and/or C-peptide
- 243. Fructosamine

LIPIDS

- 244. Cholesterol including total, HDL, LDL (calculated and/or direct)
- 245. Triglycerides
- 246. Apolipoproteins (A & B)
- 247. Chylomicron
- 248. Lipoprotein electrophoresis
- 249. Lp(a)
- 250. Lipid particle size analysis (e.g., VAP)

HEME DERIVATIVES

- 251. Hemoglobins (e.g., electrophoresis)
- 252. Myoglobin
- 253. Bilirubin
- 254. Porphyrin, precursors and derivatives (e.g., porphobilinogen, 5-aminolevulinic acid)
- 255. Iron/TIBC
- 256. Ferritin

PROTEINS AND OTHER NITROGEN-CONTAINING COMPOUNDS

- 257. Total Protein (including albumin)
- 258. Urine albumin (high sensitivity, microalbumin)
- 259. Protein electrophoresis
- 260. Immunofixation electrophoresis
- 261. Newborn screening (e.g., amino acids, inborn errors of metabolism)
- 262. Free light chains
- 263. Beta-2 microglobulin
- 264. Alpha-1 antitrypsin
- 265. C3, C4
- 266. BNP
- 267. Ceruloplasmin
- 268. C-reactive protein/hsCRP
- 269. Haptoglobin
- 270. Immunoglobulins (IgG, IgA, IgM)
- 271. IgE

| |
|--|
| 272. Transferrin |
| 273. Urea |
| 274. Uric acid |
| 275. Creatinine/eGFR |
| 276. Creatinine clearance |
| 277. Ammonia |
| 278. Routine tumor markers, (e.g., CEA, PSA, CA125) |
| 279. Special tumor markers (e.g., AFP, thyroglobulin, CA15-3, CA19-9) |
| 280. Fetal fibronectin |
| 281. Troponin |
| 282. Procalcitonin |
| 283. Nutritional markers (e.g., prealbumin) |
| |
| ENZYMES |
| 284. Creatine kinase (CK-MB, CK-MM) |
| 285. Lactate dehydrogenase (LD) |
| 286. Alanine aminotransferase (ALT) |
| 287. Aspartate aminotransferase (AST) |
| 288. Alkaline phosphatase (ALP) |
| 289. Gamma-glutamyl transferase (GGT) |
| 290. Serum cholinesterase |
| 291. Lipase/Amylase |
| 292. Glucose 6-phosphate dehydrogenase (G-6-PD) |
| |
| BLOOD GASES |
| 293. pO_2 , pCO_2 , pH |
| 294. Calculated blood gas parameters (e.g., $p50$, % saturation, base excess) |
| 295. Carbon monoxide |
| |
| ELECTROLYTES |
| 296. Potassium, sodium, chloride, CO_2 , bicarbonate |
| 297. Sweat test |
| 298. Calcium |
| 299. Magnesium |
| 300. Phosphorus |
| 301. Osmolality (measured and calculated) |
| 302. Calculated electrolyte parameters (e.g., anion gap/osmolal gap) |
| |
| HORMONES |
| 303. TSH |
| 304. Total T3 |
| 305. Free T3 |
| 306. Total and free T4 |

| |
|--|
| 307. TSH stimulation |
| 308. Cortisol |
| 309. HCG (quantitative) |
| 310. Luteinizing hormone (LH)/Follicle stimulating hormone (FSH) |
| 311. Parathyroid hormone (PTH) |
| 312. Estrogens |
| 313. Progesterone |
| 314. Testosterone |
| 315. Prolactin |
| 316. ACTH stimulation/dexamethasone suppression |
| 317. Renin/aldosterone |
| 318. 17-OH progesterone |
| 319. Growth hormone/IGF-1 |
| 320. ADH (AVP) |
| |
| VITAMINS |
| 321. Vitamin D |
| 322. Vitamin B12/Folate |
| 323. Homocysteine |
| 324. Miscellaneous vitamins (e.g., A, B6, C) |
| |
| TOXICOLOGY |
| 325. Ethanol |
| 326. Volatiles (e.g., ethylene glycol, methanol, isopropanol) |
| 327. Lead |
| 328. Heavy metals (e.g., arsenic, mercury, bismuth) |
| 329. Analgesics (e.g., acetaminophen, salicylates) |
| 330. Drugs of abuse – class analyses/screening |
| 331. Drugs of abuse – identification/confirmation/quantitation |
| 332. Trace elements (e.g., copper, selenium) |
| |
| THERAPEUTIC DRUG MONITORING |
| 333. Aminoglycosides (e.g., gentamicin) |
| 334. Cardioactive (e.g., digoxin) |
| 335. Anti-convulsants (e.g., phenobarbital, diazepam, topiramate, levetiracetam) |
| 336. Anti-depressants |
| 337. Immunosuppressants (e.g., tacrolimus, sirolimus) |

HEMATOLOGY

KNOWLEDGE QUESTIONS

338. Normal and abnormal physiology of erythrocytes, leukocytes, and platelets (e.g., production, destruction, function)

339. Physiology of hemostasis and thrombosis (e.g., pathways – extrinsic, intrinsic, common & fibrinolytic, vascular system)

340. Correlation of patient results with disease states of erythrocytes, leukocytes, and hemostasis

PERIPHERAL BLOOD EVALUATION

341. Automated cell counts and differentials

342. Peripheral blood smears for differentials (preparation and staining)

343. Manual differentials and peripheral smear evaluation (e.g., WBC, RBC, and platelet)

344. Manual cell counts (WBCs and platelets)

345. Estimation of leukocyte and platelet counts from a stained blood smear

346. Recognition of immature, reactive, malignant, or abnormal nucleated cells and leukocyte inclusions

347. Recognition of abnormalities that will interfere with automated results (e.g., platelet clumps, lipemia)

348. Correction of counts for the presence of nucleated red cells

349. Description and grading of red cells according to size, color, shape and inclusions

HEMATOLOGY TESTING

350. ESR (erythrocyte sedimentation rate)

351. Manual hematocrit

352. Fetal hemoglobin (Kleihauer Betke)

353. Hemoglobin F (quantitative)

354. Heinz body screen

355. Automated reticulocyte count

356. Reticulocyte count using microscopy

357. Sick cell screen

358. Calculate/evaluate RBC indices including MCV, MCH, MCHC, RDW

359. Hemoglobin electrophoresis

360. RBC enzymes (e.g., G-6-PD, pyruvate kinase)

361. Blood parasite screens (e.g., malaria, Babesia)

362. Flow cytometric phenotyping

363. Molecular genetic testing (e.g., FISH, PCR)

BONE MARROW EXAMINATION

364. Bone marrow procedure assistance

365. Bone marrows and/or biopsy material processing and staining

366. Bone marrow differentials (e.g., evaluate cellularity, classify various cell families, recognize abnormal and atypical cells and metastatic tumor cells)

367. Flow cytometry analysis (e.g., immunophenotyping)

368. Special stains: esterases, myeloperoxidase

| |
|---|
| 369. Iron stain (e.g., Prussian blue) |
| 370. Molecular studies (e.g., PCR, FISH, microarray) |
| 371. WHO classification |
| 372. FAB classification |
| |
| HEMOSTASIS (COAGULATION) TESTING |
| 373. Semi-automated coagulation analyzer |
| 374. Automated coagulation analyzer |
| 375. PT/INR |
| 376. APTT |
| 377. Thrombin time |
| 378. Fibrinogen |
| 379. D-dimer |
| 380. Mixing studies |
| 381. Factor assays |
| 382. vWF assays |
| 383. Heparin neutralization/adsorption (e.g., Hepzyme) |
| 384. Lupus anticoagulant (e.g., dRVVT, phospholipid neutralization) |
| 385. Factor VIII inhibitors/Bethesda titer |
| 386. Heparin assay (anti-Xa assay) |
| 387. Target-specific anticoagulant assays (e.g., dabigatran, rivaroxiban) |
| 388. Hypercoagulability tests (e.g., protein C, protein S, antithrombin) |
| 389. Hypercoagulable molecular testing (e.g., Factor V Leiden, prothrombin gene mutation) |
| 390. Activated protein C resistance |
| 391. Platelet function screening tests (e.g., PFA-100TM) |
| 392. Platelet function/diagnostic tests (e.g., platelet aggregation) |
| 393. Heparin induced thrombocytopenia (e.g., HIT studies) |
| 394. Thromboelastography (TEG) |
| |
| |
| URINALYSIS |
| KNOWLEDGE QUESTIONS |
| 395. Normal and abnormal physiology of the urinary system |
| 396. Correlation of patient results with disease states |
| URINALYSIS TASKS |
| 397. Appearance (e.g., color, clarity) |
| 398. Chemical exam (reagent strip) |
| 399. Microscopic exam (e.g., casts, cells, crystals, artifacts) |
| 400. Specific gravity by refractometer |
| 401. Confirmatory testing for reducing substances (e.g., Clinitest) |
| 402. Confirmatory testing for bilirubin (e.g., Ictotest) |

403. Confirmatory testing for proteins (e.g., SSA)

404. Confirmatory testing for ketones (e.g., Acetest)

405. Osmolality

406. Qualitative pregnancy test

407. Automated urine reagent strip reading device

408. Automated urine sediment analyzer